Swami U, Xie B, Young C, Ramaswamy K, et al. Real-world prevalence of adverse events with first-line systemic therapies among patients with metastatic castration-sensitive prostate cancer. Prostate 2024 Aug 20. doi: 10.1002/pros.24777.
PMID: 39162127